First Author: M.Kalanov RUSSIA
Co Author(s): T. Gilmanshin R. Fayzrakhmanov M. Bikbov R. Zaynullin V. Salavatova
Back to previous
To estimate the characteristics and extent of functional changes in the macular area in central retinal vein occlusion in the course of anti-VEGF therapy.
Ufa Eye Research Institute, Ufa, Russia.
We examined 37 patients (37 eyes) with the first identified thrombosis of central retinal vein occlusion. Duration of the disease from the moment of appearance of specific complaints to the moment of examination equaled from 2 weeks to 6 months. Previously, there was no special treatment. The criterion for exclusion from the study was concomitant diseases of the retina. The period of postoperative follow-up was 1 month. The intravitreal injection of the anti-VEGF preparation ranibizumab (LSR-004567/ from 08, 2008-06-16 Novartis Pharma SteinAG, Switzerland) was performed in a dose of 0.05 ml (0.5 mg) once. All patients underwent a standard ophthalmic examination, including optical coherence tomography (OCT) (RetinaScan-3000 (NIDEK), Computer Microperimetry (MP1 Microperimeter, Nidek Technologies). Protocol of microperimetry: 45 points of the presented pattern are investigated in 4 circular sectors and at the central part of the foveolar zone. Standard stimulus: size 0.43 ° (Goldmann III), duration 200 ms. The statistical processing of the results was carried out using Statistica 7.0 (Statsoft). Differences were considered significant at p <0.05.
Comparative analysis of the obtained data showed that a slight improvement of the visual acuity in 1.5 times was observed in 1 month after anti-VEGF therapy: before treatment – 0.09 ± 0.03, after – 0.14 ± 0.06 (p>0.05). A significant increase in the average index of total photosensitivity was 2.2 times (M ± m, dB): before treatment – 2.53 ± 0.15, after – 5.66 ± 0.34 (p> 0.05). The average parameters of retina photosensitivity on 4 circular sectors and at the centre of foveolar zone (M ± m, dB): zone 1 before treatment – 3.11 ± 0.2, after – 6.56 ± 0.39 (p <0.001); zone 2 before treatment – 2.94 ± 0.15, after – 5.5 ± 0.62 (p <0.01); zone 3 before treatment – 1.59 ± 0.12, after – 4.94 ± 0.94 (p <0.01); zone 4 before treatment – 1.0 ± 0.18, after – 4.63 ± 1.46 (p <0.05); central region before treatment– 0.25 ± 0.25, after – 3.5 ± 1.7.
1. In order to improve the effectiveness of treatment and the dynamic control of patients with occlusive processes of retinal veins, it is reasonable to use microperimetry. 2. The intravitreal injection of ranibizumab contributes to the pronounced positive dynamics of the parameters of the photosensitivity of the retina with a slight increase in visual acuity in patients.